Affordable Access

deepdyve-link
Publisher Website

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.

Authors
  • Jeyaraman, Preethi1
  • Agrawal, Narendra2
  • Bhargava, Rahul3
  • Bansal, Divya4
  • Ahmed, Rayaz2
  • Bhurani, Dinesh2
  • Bansal, Sachin3
  • Rastogi, Neha3
  • Borah, Pronamee1
  • Naithani, Rahul5
  • 1 Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India. , (India)
  • 2 Rajiv Gandhi Cancer Institute, New Delhi, India. , (India)
  • 3 Fortis Memorial Hospital, Gurugram, India. , (India)
  • 4 Manipal Hospital, New Delhi, India. , (India)
  • 5 Department of Hematology& Bone Marrow Transplantation, Max Superspecialty Hospital, Saket, New Delhi, 110017, India. Electronic address: [email protected] , (India)
Type
Published Article
Journal
Transfusion and Apheresis Science
Publisher
Elsevier
Publication Date
Feb 03, 2021
Pages
103075–103075
Identifiers
DOI: 10.1016/j.transci.2021.103075
PMID: 33574010
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Data on convalescent plasma therapy (CPT) in patients of hematological malignancies with severe Covid-19 is scarce. To study 14-day mortality in patients who received CPT. Retrospective multicentre observational study conducted in 4 centres treating haematological malignancies across Delhi-national capital region. Total 33 haematological malignancies patients with severe Covid-19 who received CPT were analysed. The median age of the study cohort was 62 years (18-80 years). Twenty one percent patients had 1 comorbidity, 18 % had 2 comorbidities and 6% patients had 3 and 5 comorbidities each. Twenty four patients were on active therapy. Sixty nine percent of patients required ICU stay. Twenty five patients received plasma therapy within 7 days (early) of diagnosis of Covid-19 infection. Median day of plasma infusion from date of diagnosis of Covid-19 infection was 4 days (range: 2-25 days). Patient who had early initiation of plasma therapy had shorter duration of hospitalisation (12.7 vs 24.3 days, p = 0.000). Overall mortality in the cohort was 45.5%. There was no effect of disease status, active therapy, presence of comorbidity on mortality. There was no difference in the mortality in patients receiving early vs late initiation of plasma therapy or in patients receiving one versus two plasma therapy. We provide a large series of patients with hematological malignancies and role of CPT in this group. Copyright © 2021 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times